Thousands of American pharmacies have shuttered over the past five years.
Articles on Pharmacy benefit managers
Displaying all articles
As the middlemen between drug companies and insurers, PBMs are shoo-ins as the villains behind high drug prices. But they do play a useful role in the health marketplace.
The murder of a health care insurance executive has brought scrutiny to the ways that insurance companies can make it difficult for insured patients to get the care they need.
High prescription drug costs are a widespread concern for consumers and policymakers. For patients who need specialty drugs, though, the problem is even worse, with no relief in sight.
Noted physician and author Atul Gawande was named CEO of a new health care venture aimed at cutting costs and improving care. But the most important man to keep an eye on in this effort isn’t Gawande. It’s the middleman.
CVS, which operates nearly 10,000 pharmacies across the country, announced intentions to buy Aetna, the nation’s third-largest provider of health insurance. Here’s how consumers could be affected.
Top contributors
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
Professor of Health Finance, Weatherhead School of Management & School of Medicine, Case Western Reserve University
-
Associate Professor of Health Law, Policy and Management, Boston University
-
Assistant Professor of Health Services Administration, University of Alabama at Birmingham
-
Wexler Professor of Management, Economics and Public Policy, Boston University
-
Assistant Professor of Pharmacy, University of Pittsburgh
-
Assistant Professor of Pharmacy Practice and Science, The Ohio State University
-
Associate Professor of Economics and Medicine, Case Western Reserve University
-
Associate Professor of Pharmacy and Therapeutics, University of Pittsburgh